Last reviewed · How we verify
Norco Pill
Norco combines hydrocodone (an opioid agonist) with acetaminophen to provide pain relief through central nervous system depression and peripheral analgesic effects.
Norco combines hydrocodone (an opioid agonist) with acetaminophen to provide pain relief through central nervous system depression and peripheral analgesic effects. Used for Moderate to moderately severe acute pain.
At a glance
| Generic name | Norco Pill |
|---|---|
| Sponsor | Rothman Institute Orthopaedics |
| Drug class | Opioid analgesic combination |
| Target | Mu-opioid receptor (hydrocodone component); COX enzymes and serotonergic pathways (acetaminophen component) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Hydrocodone binds to mu-opioid receptors in the central nervous system to reduce pain perception and emotional response to pain. Acetaminophen works through multiple mechanisms including COX inhibition and serotonergic pathways to provide additional analgesic and antipyretic effects. The combination provides synergistic pain relief for moderate to moderately severe pain.
Approved indications
- Moderate to moderately severe acute pain
Common side effects
- Dizziness
- Lightheadedness
- Drowsiness
- Nausea
- Constipation
- Respiratory depression
Key clinical trials
- Opioid Analgesic Reduction Study (PHASE3)
- Efficacy of Methylprednisolone for Pain Control After ACL Repair (PHASE4)
- Hip Arthroscopy Postoperative Opioid Demands (NA)
- Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia (PHASE3)
- Effect of Ibuprofen on Postoperative Opiate Medication Use and Shoulder Functional Outcomes (NA)
- Ibuprofen to Decrease Opioid Use and Post-operative Pain Following Unilateral Inguinal Herniorrhaphy (PHASE3)
- Reducing Opioid Use and Misuse After Wisdom Molar Extractions (PHASE2)
- Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Norco Pill CI brief — competitive landscape report
- Norco Pill updates RSS · CI watch RSS
- Rothman Institute Orthopaedics portfolio CI